We are very happy to attend the 4th Annual Novel Conjugates Summit of Boston 2025, organized by Hanson Wade from 25th to 27th of March.
The 4th Novel Conjugates Summit returns to showcase the fresh approaches biopharma are taking in developing ADCs with alternative payloads and targeting formats.
The focus of this summit is the exploration to pushing the boundaries of what’s Conjugatable to assess how Novel format & Payload conjugates can deliver more targeted & safer treatments to a wider Patient population.
With 100+ industry colleagues from large pharma, biotechs with expertise in specialized approaches, start-ups, service providers with expertise in conjugating and manufacturing and providers of novel targeting, whether it be antibody-degrader conjugates, bispecific-drug conjugates, peptide-drug conjugates, antibody-oligonucleotide conjugates and more; The summit is the space to share learnings and understand the value proposition of each approach to fuel further advancement and innovation.
BSP's team looks forward to meeting You at our booth in the Exhibitor area
To request a meeting and for any other info, You can send an e-mail at Business.Development@Bsppharmaceuticals.com
Save the Date!!! Next Thursday, 27th March 2025, our Giorgio Salciarini, Head of Sales, Technical Business Development, will presents to other guests its speech "Supporting Novel bioconjugates from IND to Commercial Supply" during the Conference Day2, from 10:O0 AM.
